🇺🇸 FDA
Patent

US 12202902

FLT3-specific chimeric antigen receptors and methods using same

granted A61KA61K2039/505A61K2239/31

Quick answer

US patent 12202902 (FLT3-specific chimeric antigen receptors and methods using same) held by The United States of America, as represented by the Secretary, Department of Health and Human Services expires Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
The United States of America, as represented by the Secretary, Department of Health and Human Services
Grant date
Tue Jan 21 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 16 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
19
CPC classes
A61K, A61K2039/505, A61K2239/31, A61K2239/38, A61K2239/48